Series A · Biotech · Cambridge, United Kingdom · Founded 2018 · 14–26 employees
Abselion develops practical measurement tools that simplify biomolecule quantification using proprietary Redox Electrochemical Detection (RED) technology. Their flagship Amperia system enables rapid protein quantification directly from crude samples in just one minute, eliminating the complexity of traditional analytical methods. The Cambridge University spin-out recently secured £6.6 million in Series A funding led by M Ventures to commercialize their award-winning technology. They have established a US subsidiary at The Engine in Cambridge, MA to support growing international adoption across life sciences and bioprocessing markets.
No open roles listed right now.